Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The PEDI-NAD Trial: Injectable Nicotinamide Adenine Dinucleotide (NAD⁺) for Pediatric Cardiac Dysfunction: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Protocol

NCT07839130 is registered in ClinicalTrials.gov with Beijing Children's Hospital as lead sponsor.

NCT NCT07839130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07839130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The PEDI-NAD Trial: Injectable Nicotinamide Adenine Dinucleotide (NAD⁺) for Pediatric Cardiac Dysfunction: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Protocol
Lead sponsor
Beijing Children's Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 1, 2028
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac dysfunction